Home / Science / New £20m AI Hub Boosts Drug Development
New £20m AI Hub Boosts Drug Development
17 Aug
Summary
- A new £20m research hub will develop medicines using AI.
- The hub uses human tissue models and AI to test treatments.
- It aims for more effective, personalized therapies with reduced costs.
A significant new £20 million research hub is set to launch in Cambridge, dedicated to advancing medicine development through artificial intelligence and sophisticated laboratory models. This facility will be situated at the Cambridge Stem Cell Institute, a part of the Cambridge Biomedical Campus.
The Medical Research Council is funding this initiative, which will collaborate closely with Cambridge University Hospitals NHS Foundation Trust. Researchers will employ scientific models derived from human tissues and diseases to enhance the transition of laboratory findings into practical new medicines.
This hub will enable more accurate methods for studying and predicting human diseases, and for developing treatments before they are tested on patients. It also supports efforts to reduce the reliance on animal research. By leveraging lab-grown mini-organs called organoids, stem cell systems, and AI, the hub seeks to create more effective, personalized therapies.
The initiative is expected to significantly reduce the time and cost associated with drug development. Led by Professor Matthias Zilbauer and Professor Bertie Göttgens, the hub will unite hospitals, research institutes, and industry partners across the UK to accelerate the creation and implementation of new research tools that better mirror human biology.
